Moderna's mRNA Vaccines vs. Neoantigen Therapies: Navigating the Gray Area of Terminology and Public Perception
Original framing: “What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma” — MIT Technology Review
This framing omits the historical context of vaccine development and the role of indigenous knowledge in shaping our understanding of immunity. It also fails to consider the structural causes of vaccine skepticism, such as the lack of trust in institutions and the influence of misinformation. Furthermore, the narrative neglects to include marginalized perspectives on the use of mRNA technology, particularly from communities of color who have historically been disproportionately affected by vaccine-related health disparities.
Medium structural omission detected in mainstream coverage.
This narrative was produced by MIT Technology Review, a publication known for its in-depth coverage of emerging technologies. The framing of this story serves to highlight the complexities of public perception and the need for nuanced communication, while also obscuring the broader structural issues surrounding the development and deployment of mRNA vaccines. The framing also serves to reinforce the power dynamics between the scientific community and the general public.
The development of mRNA vaccines is part of a longer history of vaccine development that dates back to the 18th century. Understanding the historical context of vaccine development is crucial for appreciating the complexities of public perception and the need for nuanced communication.
The debate over whether Moderna's mRNA vaccines should be referred to as 'vaccines' or 'therapies' highlights the complexities of public perception and the need for nuanced communication.